SGLT2 inhibitors, via amplifying the effect of fasting moderately increases LDL-cholesterol and ketone levels

被引：0
|
作者：
Mayoux, E. [1 ]
Briand, F. [2 ]
Sulpice, T. [2 ]
Luippold, G. [1 ]
Mark, M. [1 ]
机构：
[1] Boehringer Ingelheim GmbH & Co KG, Cardiometab, Biberach, Germany
[2] Physiogenex, Toulouse, France
来源：
DIABETOLOGIA | 2016年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
739
引用
收藏
页码：S352 / S352
页数：1
相关论文
共 10 条
  • [1] Empagliflozin moderately increases LDL-cholesterol levels through reduced LDL catabolism while it increases slightly the reverse cholesterol in hamsters
    Briand, F.
    Burr, N.
    Urbain, I.
    Mayoux, E.
    Sulpice, T.
    [J]. DIABETOLOGIA, 2015, 58 : S359 - S360
  • [2] Effect of Lactobacillus plantarum (pro viva) on LDL-cholesterol and fibrinogen levels in subjects with moderately elevated cholesterol
    Bukowska, H
    PieczulMroz, J
    Chelstowski, K
    Naruszewicz, M
    [J]. ATHEROSCLEROSIS, 1997, 134 (1-2) : 325 - 325
  • [3] Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component?
    Prattichizzo, Francesco
    De Nigris, Valeria
    Micheloni, Stefano
    La Sala, Lucia
    Ceriello, Antonio
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (11): : 2515 - 2522
  • [4] Empagliflozin Moderately Increases LDL-Cholesterol Levels Only under Dyslipidemia and Chronic Treatment, and Does Not Change LDL Particles Size in Golden Syrian Hamsters
    Briand, Francois
    Urbain, Isabelle
    Brousseau, Emmanuel
    Sulpice, Thierry
    Mark, Michael
    Mayoux, Eric W., Sr.
    [J]. DIABETES, 2017, 66 : A599 - A599
  • [5] Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism
    Briand, Francois
    Mayoux, Eric
    Brousseau, Emmanuel
    Burr, Noemie
    Urbain, Isabelle
    Costard, Clement
    Mark, Michael
    Sulpice, Thierry
    [J]. DIABETES, 2016, 65 (07) : 2032 - 2038
  • [6] In Rodents, Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Moderately Increase Blood Ketones thus Amplifying the Effects of Fasting
    Mayoux, Eric W.
    Faessler, Julia
    Hertenberger, Carina
    Mark, Michael
    Luippold, Gerd
    [J]. DIABETES, 2016, 65 : A310 - A310
  • [7] SGLT2 INHIBITORS MAY REVERSE THE DAMAGING EFFECT OF OXIDIZED CHOLESTEROL ON THE INTEGRITY OF HUVECS AND ALLEVIATE ASSOCIATED INFLAMMATORY RESPONSE
    Pawlos, A.
    Broncel, M.
    Wozniak, E.
    Gorzelak-Pabis, P.
    [J]. ATHEROSCLEROSIS, 2022, 355 : E88 - E89
  • [8] NOVEL MOLECULAR MECHANISMS IN THE RENOPROTECTIVE EFFECT OF SGLT2 INHIBITORS VIA MITIGATION OF TUBULAR HYPOXIA AND PROTEIN O-GLCNACYLATION
    Balogh, Dora
    Hodrea, Judit
    Lenart, Lilla
    Hosszu, Adam
    Mezei, Csenge
    Vannay, Adam
    Wagner, Laszlo
    Szabo, Attila
    Fekete, Andrea
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [9] Effect of Raised Alanine Transaminase (ALT) Levels on HbA1c in the Association of British Clinical Diabetologists (ABCD) Nationwide Audits of SGLT2 Inhibitors (SGLT2i)
    Deshmukh, Harshal
    Bickerton, Alex
    Phillips, Suzanne M.
    Evans, Alison
    Raghavan, Rajeev P.
    Sennik, Devesh K.
    Rohilla, Anurita
    Adamson, Karen
    Yadagiri, Mahender
    Gallen, Ian W.
    Ryder, Robert E.
    Sathyapalan, Thozhukat
    [J]. DIABETES, 2020, 69
  • [10] Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials
    Yip, Alicia Swee Yan
    Leong, Shariel
    Teo, Yao Hao
    Teo, Yao Neng
    Syn, Nicholas L. X.
    See, Ray Meng
    Wee, Caitlin Fern
    Chong, Elliot Yeung
    Lee, Chi-Hang
    Chan, Mark Y.
    Yeo, Tiong-Cheng
    Wong, Raymond C. C.
    Chai, Ping
    Sia, Ching-Hui
    [J]. THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2022, 13
1